G6PC2

Across TCGA pan-cancer cohorts, G6PC2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of G6PC2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where G6PC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types G6PC2 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where G6PC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in G6PC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.162	<.001	10	view →
LUAD	Female	All	−0.143	<.001	7	view →
LUSC	All	II,III,IV	−0.150	<.001	6	view →
UCEC	All	All	−0.060	.003	6	view →
COAD	All	II,III,IV	−0.052	.007	5	view →
KICH	All	All	−0.082	.001	4	view →
HNSC	All	All	−0.017	.021	4	view →
CHOL	Male	All	+0.075	.042	1	view →
THCA	Male	II,III,IV	−0.014	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

G6PC2–KIRC

Open the KIRC breakdown →